Johnson & Johnson has won FDA approval for IMAAVY as the first treatment specifically for warm autoimmune hemolytic anemia, backed by Phase 2/3 trial data.
#Biotech #Biotechnology #RareDisease #Health #HealthInnovation
Disclaimer: This is NOT a financial advice
Johnson & Johnson has won FDA approval for IMAAVY as the first treatment specifically for warm autoimmune hemolytic anemia, backed by Phase 2/3 trial data. #Biotech #Biotechnology #RareDisease #Health #HealthInnovation Disclaimer: This is NOT a financial advice
0 vue
Publié le 27/08/2026 00:23
Johnson & Johnson has won FDA approval for IMAAVY as the first treatment specifically for warm autoimmune hemolytic anemia, backed by Phase 2/3 trial data.
#Biotech #Biotechnology #RareDisease #Health #HealthInnovation
Disclaimer: This is NOT a financial advice
0 commentaire
?